

Boston Scientific

Boston Scientific Appoints Steven L. Zelenkofske Patient Safety Officer and Vice President, Clinical Sciences for Cardiac Rhythm Management Group

PRNewswire-FirstCall
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., Oct. 31 /[PRNewswire-FirstCall](#)/ -- Boston Scientific Corporation (NYSE: BSX) today announced that Steven L. Zelenkofske, D.O., F.A.C.C., has been appointed Patient Safety Officer and Vice President of Clinical Sciences for the Company's Cardiac Rhythm Management (CRM) Group. In this new role, he will lead the development and implementation of pre- and post-market clinical strategy that supports the Company's CRM technology and therapy portfolio. He will also be responsible for enhancing the internal structure, organization and processes for CRM patient safety. He joined Boston Scientific earlier this month and is located in St. Paul, Minnesota. Dr. Zelenkofske reports to Fred Colen, Executive Vice President, Operations and Technology -- CRM and Chief Technology Officer at Boston Scientific.

"Steve's energy and passion for improving the lives of patients, along with his leadership experiences within the cardiovascular industry, make him an excellent choice to lead Boston Scientific CRM patient safety and clinical sciences functions," said Colen. "His depth of experience in cardiovascular clinical research and broad knowledge of cardiac rhythm management has allowed him to make immediate contributions. I am excited to have Steve on the CRM team."

Before joining Boston Scientific CRM, Zelenkofske was a senior director with Novartis Pharmaceuticals, where he held positions of increasing responsibility within its cardiovascular division since 2002. He is a practicing electrophysiologist (EP) and serves as an associate professor of medicine at the College of Medicine of the Pennsylvania State University/Hershey Medical Center and for the Philadelphia College of Osteopathic Medicine. Dr. Zelenkofske is an active staff member at Muhlenberg Hospital Center in Bethlehem, Pennsylvania and Lehigh Valley Hospital in Allentown, Pennsylvania. He has served as a physician investigator for a number of pivotal cardiovascular clinical trials, including SCD HeFT, COMPANION, MADIT, AVID and MUSTT. He is the author or co-author of numerous articles published in professional journals such as the New England Journal of Medicine, Circulation, American Heart Journal and the European Heart Journal. He is a regular presenter at scientific sessions and other professional meetings.

Dr. Zelenkofske earned his medical degree from the Philadelphia College of Osteopathic Medicine and holds certifications in clinical cardiac electrophysiology, cardiology and internal medicine. He is an active member of the American College of Cardiology, Heart Rhythm Society, American Heart Association, Heart Failure Society of America, American Society of Hypertension, American College of Chest Physicians, American College of Osteopathic Internists and several other professional societies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: <http://www.bostonscientific.com/>.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

CONTACT:
Milan Kofol
508-650-8569 (office)
617-834-8595 (mobile)
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Milan Kofol, +1-508-650-8569 (Office) or 617-834-8595 (Mobile), Investor Relations, or Paul Donovan, +1-508-650-8541 (Office), or +1-508-667-5165 (Mobile), Media Relations, both of Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=58905>